A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2-microglobulin

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

(2013) Z. Zhou et al.   BLOOD

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

(2011) G. Gutierrez-Garcia et al.   BLOOD

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper

(2010) M. Aapro et al.   ANNALS OF ONCOLOGY

Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States

(2010) Pareen J. Shenoy et al.   CANCER

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

(2010) Paul N. Meyer et al.   JOURNAL OF CLINICAL ONCOLOGY